274 related articles for article (PubMed ID: 30074120)
1. Minimally interrupted novel oral anticoagulant versus uninterrupted vitamin K antagonist during atrial fibrillation ablation.
De Heide J; Vroegh CJ; Bhagwandien RE; Wijchers SA; Szili-Torok T; Zijlstra F; Lenzen MJ; Yap SC
J Interv Card Electrophysiol; 2018 Dec; 53(3):341-346. PubMed ID: 30074120
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation.
Mao YJ; Wang H; Huang PF
J Interv Card Electrophysiol; 2021 Apr; 60(3):407-417. PubMed ID: 32361948
[TBL] [Abstract][Full Text] [Related]
3. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
4. Minimally Interrupted Non-Vitamin K Antagonist Oral Anticoagulants vs. Bridging Therapy and Uninterrupted Vitamin K Antagonists During Atrial Fibrillation Ablation: A Retrospective Single-Center Study.
Tang L; Liu H; Deng H; Zhan X; Fang X; Liao H; Liu Y; Fu L; Fu Z; Liu H; Wu S; Xue Y
Front Med (Lausanne); 2020; 7():197. PubMed ID: 32582721
[No Abstract] [Full Text] [Related]
5. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
[TBL] [Abstract][Full Text] [Related]
6. Interrupted or Uninterrupted Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation.
Yang P; Wang C; Ye Y; Huang T; Yang S; Shen W; Xu G; Wu Q
Cardiovasc Drugs Ther; 2020 Jun; 34(3):371-381. PubMed ID: 32232617
[TBL] [Abstract][Full Text] [Related]
7. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial.
Reynolds MR; Allison JS; Natale A; Weisberg IL; Ellenbogen KA; Richards M; Hsieh WH; Sutherland J; Cannon CP
JACC Clin Electrophysiol; 2018 May; 4(5):580-588. PubMed ID: 29798783
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation.
Ukaigwe A; Shrestha P; Karmacharya P; Hussain SK; Samii S; Gonzalez MD; Wolbrette D; Naccarrelli GV
J Interv Card Electrophysiol; 2017 Mar; 48(2):223-233. PubMed ID: 27771820
[TBL] [Abstract][Full Text] [Related]
9. Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
Li PJ; Xiao J; Yang Q; Feng Y; Wang T; Liu GJ; Liang ZA
J Interv Card Electrophysiol; 2016 Sep; 46(3):213-24. PubMed ID: 27001171
[TBL] [Abstract][Full Text] [Related]
10. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
[TBL] [Abstract][Full Text] [Related]
11. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies.
Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F
Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
13. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
[TBL] [Abstract][Full Text] [Related]
14. Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.
Wang CL; Wu VC; Huang YT; Chen YL; Chu PH; Kuo CF; Wen MS; Chang SH
J Thromb Thrombolysis; 2021 Jan; 51(1):58-66. PubMed ID: 32409936
[TBL] [Abstract][Full Text] [Related]
15. Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias.
Bawazeer GA; Alkofide HA; Alsharafi AA; Babakr NO; Altorkistani AM; Kashour TS; Miligkos M; AlFaleh KM; Al-Ansary LA
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013504. PubMed ID: 34674223
[TBL] [Abstract][Full Text] [Related]
16. Comparison of major bleeding events of uninterrupted non-vitamin K antagonist oral anticoagulants versus uninterrupted vitamin K antagonist during catheter ablation of atrial fibrillation: a meta-analysis of randomised controlled trials.
Yang Q; Chen X; Zhai J; Dang Y
Acta Cardiol; 2022 May; 77(3):257-263. PubMed ID: 33871328
[TBL] [Abstract][Full Text] [Related]
17. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
Romero J; Cerrud-Rodriguez RC; Diaz JC; Michaud GF; Taveras J; Alviz I; Grupposo V; Cerna L; Avendano R; Kumar S; Kirchhof P; Natale A; Di Biase L
Europace; 2018 Oct; 20(10):1612-1620. PubMed ID: 29982383
[TBL] [Abstract][Full Text] [Related]
18. Cerebral thromboembolic risk in atrial fibrillation ablation: a direct comparison of vitamin K antagonists versus non-vitamin K-dependent oral anticoagulants.
Petzl A; Derndorfer M; Kollias G; Moroka K; Aichinger J; Pürerfellner H; Martinek M
J Interv Card Electrophysiol; 2021 Jan; 60(1):147-154. PubMed ID: 32144677
[TBL] [Abstract][Full Text] [Related]
19. Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials.
Cardoso R; Willems S; Gerstenfeld EP; Verma A; Schilling R; Hohnloser SH; Okumura K; Nordaby M; Brouwer MA; Calkins H
Clin Cardiol; 2019 Jan; 42(1):198-205. PubMed ID: 30460702
[TBL] [Abstract][Full Text] [Related]
20. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation.
Calkins H; Willems S; Gerstenfeld EP; Verma A; Schilling R; Hohnloser SH; Okumura K; Serota H; Nordaby M; Guiver K; Biss B; Brouwer MA; Grimaldi M;
N Engl J Med; 2017 Apr; 376(17):1627-1636. PubMed ID: 28317415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
